白蛋白-胆红素分级改善索拉非尼治疗失败后肝脏储备功能评估:对药物开发的启示
研究基于447例连续转诊的前瞻性国际数据库,纳入386例接受索拉非尼治疗的巴塞罗那临床肝癌C期患者,分析停药时临床变量对索拉非尼停药后总生存期的影响。结果显示,适合二线治疗的患者(n=294)按ALBI 1、2、3级的中位停药后总生存期分别为17.5、7.5和1.9个月(P < 0.001)。结论认为,停药时ALBI分级可识别肝脏储备功能稳定且生存更优的患者亚组,可能有助于改进晚期HCC二线治疗的患者选择。
要点
- 386例索拉非尼治疗患者中,停药后中位总生存期为3.4个月,中位索拉非尼治疗时间为2.9个月。
- 停药最常见原因为疾病进展(68%)和毒性(24%);停药时92例(24%)进展至终末期,其中40例(10%)Child分级恶化至C级。
- 适合二线治疗的患者(n=294)按ALBI 1、2、3级的中位停药后总生存期分别为17.5、7.5和1.9个月(P < 0.001)。
核心结论
- 索拉非尼停药时的ALBI分级可识别肝脏储备功能长期稳定且生存更优的患者亚组,可能有助于改进晚期HCC二线治疗的患者选择。
研究设计与样本
- 基于前瞻性维护的国际数据库,从447例连续转诊中衍生出386例在巴塞罗那临床肝癌C期接受索拉非尼治疗的患者,其中75%在起始时为Child A级。
- 采用单变量和多变量分析评估索拉非尼停药时临床变量对停药后总生存期的影响。
主要发现
- 386例合格患者的中位停药后总生存期为3.4个月,中位索拉非尼治疗时间为2.9个月。
- 停药最常见原因为疾病进展(68%)和毒性(24%)。
- 停药时92例(24%)进展至终末期,其中40例(10%)因Child分级恶化至C级。
- 适合二线治疗的患者(n=294)按ALBI 1、2、3级的中位停药后总生存期分别为17.5、7.5和1.9个月(P < 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug development in hepatocellular carcinoma (HCC) is limited by disease heterogeneity, with hepatic reserve being a major source of variation in survival outcomes. The albumin-bilirubin (ALBI) grade is a validated index of liver function in patients with HCC. AIM: To test the accuracy of the ALBI grade in predicting post-sorafenib overall survival (PSOS) in patients who permanently discontinued treatment. METHODS: From a prospectively maintained international database of 447 consecutive referrals, we derived 386 eligible patients treated with sorafenib within Barcelona Clinic Liver Cancer C stage (62%), 75% of whom were of Child class A at initiation. Clinical variables at sorafenib discontinuation were analysed for their impact on post-sorafenib overall survival using uni- and multivariable analyses. RESULTS: Median post-sorafenib overall survival of the 386 eligible patients was 3.4 months and median sorafenib duration was 2.9 months, with commonest causes of cessation being disease progression (68%) and toxicity (24%). At discontinuation, 92 patients (24%) progressed to terminal stage, due to worsening Child class to C in 40 (10%). Median post-sorafenib overall survival in patients eligible for second-line therapies (n = 294) was 17.5, 7.5 and 1.9 months according respectively to ALBI grade 1, 2 and 3 (P < 0.001). CONCLUSIONS: The ALBI grade at sorafenib discontinuation identifies a subset of patients with prolonged stability of hepatic reserve and superior survival. This may allow improved patient selection for second-line therapies in advanced HCC.
引用
- Pinato DJ, Yen C, Bettinger D, et al. The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. Aliment Pharmacol Ther. 2017. PMID: 28116800. doi:10.1111/apt.13904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。